Bristol-Myers Squibb (NYSE:BMY) Holdings Raised by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA raised its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 15.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,895 shares of the biopharmaceutical company’s stock after buying an additional 1,695 shares during the quarter. Nichols & Pratt Advisers LLP MA’s holdings in Bristol-Myers Squibb were worth $748,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Bristol-Myers Squibb by 0.9% during the 2nd quarter. State Street Corp now owns 92,570,288 shares of the biopharmaceutical company’s stock worth $5,919,870,000 after purchasing an additional 858,922 shares in the last quarter. Capital International Investors grew its holdings in shares of Bristol-Myers Squibb by 12.8% during the 2nd quarter. Capital International Investors now owns 69,296,006 shares of the biopharmaceutical company’s stock worth $4,431,517,000 after purchasing an additional 7,878,833 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 39,034,341 shares of the biopharmaceutical company’s stock worth $2,489,314,000 after purchasing an additional 225,065 shares in the last quarter. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $1,873,696,000. Finally, Moneta Group Investment Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 114,228.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock worth $1,544,751,000 after purchasing an additional 21,451,006 shares in the last quarter. Institutional investors and hedge funds own 74.98% of the company’s stock.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, Director Theodore R. Samuels II acquired 8,500 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 20th. The stock was bought at an average cost of $49.81 per share, with a total value of $423,385.00. Following the completion of the transaction, the director now directly owns 35,500 shares of the company’s stock, valued at $1,768,255. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Christopher S. Boerner acquired 2,000 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 5th. The stock was bought at an average cost of $49.78 per share, with a total value of $99,560.00. Following the completion of the transaction, the chief executive officer now directly owns 82,672 shares of the company’s stock, valued at $4,115,412.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Theodore R. Samuels II acquired 8,500 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 20th. The shares were purchased at an average cost of $49.81 per share, with a total value of $423,385.00. Following the completion of the transaction, the director now directly owns 35,500 shares of the company’s stock, valued at $1,768,255. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 13,571 shares of company stock valued at $672,994. Company insiders own 0.08% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.1 %

Shares of Bristol-Myers Squibb stock opened at $49.87 on Monday. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $73.47. The company has a quick ratio of 1.07, a current ratio of 1.18 and a debt-to-equity ratio of 1.11. The stock has a market cap of $101.47 billion, a PE ratio of 12.90, a price-to-earnings-growth ratio of 1.53 and a beta of 0.38. The business has a fifty day simple moving average of $50.52 and a 200 day simple moving average of $54.66.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.33% and a net margin of 17.83%. The firm had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. During the same period in the previous year, the firm earned $1.82 earnings per share. The company’s revenue was up .6% on a year-over-year basis. Research analysts predict that Bristol-Myers Squibb will post 6.52 EPS for the current year.

Bristol-Myers Squibb declared that its Board of Directors has approved a stock repurchase plan on Thursday, December 7th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase up to 2.9% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its stock is undervalued.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.81%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.57. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

Analysts Set New Price Targets

Several equities analysts recently commented on BMY shares. UBS Group restated a “neutral” rating and set a $60.00 target price (down previously from $70.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 20th. Deutsche Bank Aktiengesellschaft started coverage on Bristol-Myers Squibb in a research report on Thursday, November 9th. They set a “hold” rating and a $55.00 target price for the company. Wells Fargo & Company cut their target price on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. Daiwa Capital Markets downgraded Bristol-Myers Squibb from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $68.00 to $54.00 in a research report on Thursday, November 2nd. Finally, Cantor Fitzgerald downgraded Bristol-Myers Squibb from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $68.00 to $55.00 in a research report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $61.17.

View Our Latest Stock Report on BMY

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Recommended Stories

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.